Lysosomal Protease-Activated Contrast Agents for Tumor Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current contrast agents for surgical tumor imaging lack high cellular uptake, broad protease targeting, and sensitivity at clinically relevant wavelengths, limiting their effectiveness in detecting a variety of tumors and requiring new instrumentation.
Innovation Solution
Development of novel activity-based contrast agents with specific compounds represented by formulas (I) and (III), featuring fluorescent or radioactive labels, quenchers, and protease-targeting elements, optimized for enhanced sensitivity and broad protease targeting, suitable for existing clinical imaging instruments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-targeted contrast agents (ICG, fluorescein, methylene blue, 5-ALA) are used for tumor imaging, then the imaging process is simple and agents are clinically approved, but they lack tumor specificity and cannot provide targeted visualization of tumor margins
Solution Approach 1:
The contrast agent is segmented into distinct functional modules: a protease-targeting peptide sequence (e.g., ELGL or LLGL) and a fluorescent reporter group. The peptide portion enables specific binding to cathepsin B overexpressed in tumors, while the fluorophore provides optical signal. This segmentation allows the agent to achieve tumor-specific targeting without requiring complex molecular structures.
Solution Approach 2:
The contrast agent design uses a universal protease-targeting peptide sequence that can bind to cathepsin B, a protease commonly overexpressed in various tumor types including breast, lung, and colorectal cancers. This universal targeting mechanism allows a single agent design to be applicable across multiple cancer types, eliminating the need for tumor-specific customization while maintaining high detection accuracy.
2Reliability
If targeted contrast agents with complex structures are developed to improve tumor specificity, then tumor detection accuracy improves, but cellular uptake and sensitivity at clinically relevant wavelengths decrease
Solution Approach 1:
The fluorescent reporter group is specifically selected to emit in the near-infrared range (700-900 nm), which represents optimal parameters for clinical imaging applications. This wavelength range provides superior tissue penetration depth and reduced background autofluorescence compared to visible light fluorophores. The peptide- fluorophore conjugation maintains the fluorophore's quantum yield and brightness while adding targeting capability, thus improving sensitivity rather than compromising it.
3Measurement precision
If protease-activated smart probes are used to improve tumor-specific signal generation, then detection precision improves, but the agents require new instrumentation and are not compatible with existing clinical imaging tools
Solution Approach 1:
The contrast agent is designed as a small molecule peptide-fluorophore conjugate rather than a large complex requiring specialized equipment. The fluorophore emits stable fluorescence signals that can be detected by standard surgical fluorescence imaging systems already deployed in clinical settings. This design choice allows the agent to function as a disposable, single-use contrast medium that leverages existing clinical infrastructure rather than requiring new instrument development.
4Productivity
If current contrast agents are used for surgical tumor imaging, then the surgical procedure is straightforward, but complete removal of all cancer cells cannot be ensured due to poor tumor margin visualization
Solution Approach 1:
The contrast agent is administered intravenously before surgery begins, allowing sufficient time for distribution to tumor tissues and activation by cathepsin B. This preliminary administration enables tumor margins to be visualized before the surgeon makes incisions, allowing real-time guidance throughout the resection process. The agent remains active during surgery, providing continuous feedback on tumor boundaries to ensure complete removal while preserving healthy tissue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new agents provide improved tumor margin detection and visualization during surgery, with enhanced sensitivity and compatibility with existing clinical imaging tools, facilitating precise surgical resection of various tumors.
Implementation Method 1
D is a detectable element comprising a fluorescent label
Implementation Method 2
Q is a quencher
Data Source
AI summary
Compounds useful as contrast agents in image-guided surgery are provided. The compounds comprise a latent cationic lysosomotropic fragment that is detectable upon cleavage by lysosomal proteases within treated tissues, particularly within tumors and other diseased tissues. Also provided are compositions comprising the compounds and methods for using the compounds, for example in dynamically monitoring protease activity in vivo during image-guided tumor resection surgery.